Neratinib after trastuzumab in patients with HER2-positive breast cancer
- PMID: 27301038
- DOI: 10.1016/S1470-2045(16)00165-0
Neratinib after trastuzumab in patients with HER2-positive breast cancer
Comment in
-
Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply.Lancet Oncol. 2016 May;17(5):e176-7. doi: 10.1016/S1470-2045(16)30018-3. Epub 2016 Apr 27. Lancet Oncol. 2016. PMID: 27301039 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
